RT Journal Article
SR Electronic
T1 Preliminary optimisation of simplified sample preparation method to permit direct detection of SARS-CoV-2 within saliva samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.16.20155168
DO 10.1101/2020.07.16.20155168
A1 Howson, Emma L. A.
A1 Kidd, Stephen P.
A1 Sawyer, Jason
A1 Cassar, Claire
A1 Cross, David
A1 Lewis, Tom
A1 Hockey, Jess
A1 Rivers, Samantha
A1 Cawthraw, Saira
A1 Banyard, Ashley
A1 Andreou, Michael
A1 Morant, Nick
A1 Clark, Duncan
A1 Walsh, Charlotte
A1 Laxman, Shailen
A1 Houghton, Rebecca
A1 Slater-Jefferies, Joanne
A1 Costello, Paula
A1 Brown, Ian
A1 Cortes, Nicholas
A1 Godfrey, Keith M.
A1 Fowler, Veronica L.
YR 2020
UL http://medrxiv.org/content/early/2020/07/28/2020.07.16.20155168.abstract
AB We describe the optimization of a simplified sample preparation method which permits rapid and direct detection of SARS-CoV-2 RNA within saliva using reverse-transcription loop-mediated isothermal amplification (RT-LAMP). Treatment of saliva samples prior to RT-LAMP by dilution 1:1 in Mucolyse™, followed by dilution (within the range of 1:5 to 1:40) in 10% (w/v) Chelex© 100 Resin and a 98°C heat step for 2 minutes enabled detection of SARS-CoV-2 RNA in all positive saliva samples tested, with no amplification detected in pooled negative saliva. The time to positivity for which SARS-CoV-2 RNA was detected in these positive saliva samples was proportional to the real-time reverse-transcriptase PCR cycle threshold (CT), with SARS-CoV-2 RNA detected in as little as 05:43 (CT 21.08), 07:59 (CT 24.47) and 08:35 (CT 25.27) minutes, respectively. The highest CT where direct RT-LAMP detected SARS-CoV-2 RNA was 31.39 corresponding to a 1:40 dilution of a positive saliva sample with a starting CT of 25.27. When RT-LAMP was performed on pools of SARS-CoV-2 negative saliva samples spiked with whole inactivated SARS-CoV-2 virus, RNA was detected at dilutions spanning 1:5 to 1:160 representing CT’s spanning 22.49-26.43. Here we describe a simple but critical rapid sample preparation method which can be used up front of RT-LAMP to permit direct detection of SARS-CoV-2 within saliva samples. Saliva is a sample which can be collected non-invasively without the use of highly skilled staff and critically can be obtained from both health care and home settings. Critically, this approach overcomes both the requirement and validation of different swabs and the global bottleneck observed in obtaining RNA extraction robots and reagents to enable molecular testing by PCR. Such testing opens the possibility of public health approaches for effective intervention to control the COVID-19 pandemic through regular SARS-CoV-2 testing at a population scale, combined with isolation and contact tracing for positive cases.Competing Interest StatementCompeting Interest Statement: All reagents and equipment were purchased from a DHSC award to the University of Southampton (Grant Reference Number 2020/032). Emma Howson was on secondment at GeneSys Biotech Limited for the duration of this project (from The Pirbright Institute) and contributed to the generation of the data at APHA but was not involved in data analysis. All other data was generated and analysed independently of the authors from OptiSense Limited and all other authors from GeneSys Biotech Limited.Funding StatementThis work was funded by a Department of Health and Social Care award to the University of Southampton (Grant Reference Number 2020/032 (Feasibility study for city-wide testing using saliva based LAMP testing)). The views expressed are those of the authors and not necessarily those of the Department of Health and Social Care. KMG is supported by the UK Medical Research Council (MC_UU_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)) and the British Heart Foundation (RG/15/17/3174). For this project, Emma Howson was on secondment at GeneSys Biotech Ltd, which was part funded by The Pirbright Institute Flexible Talent Mobility Account (FTMA) under BBSRC grant BB/S507945/1. The analytical testing was conducted at HHFT and at Defra maintained facilities at the Animal and Plant Health Agency-Weybridge.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UHS saliva collection and analysis was conducted with informed written consent following institutional review board approval (ENACT Enabling New Approaches for CoVID-19 Treatment).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is contained within the tables in the manuscript